Annual report pursuant to Section 13 and 15(d)

Note 3 - Revenue (Tables)

v3.23.1
Note 3 - Revenue (Tables)
12 Months Ended
Dec. 31, 2022
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   

Year Ended December 31,

 
   

2022

   

2021

 

AstraZeneca

  $ 9,117     $ 18,919  

Seagen

    8,287       768  

Servier

    5,359       4,070  

Genentech

    3,139       1,950  

Boston Pharmaceuticals

          5,711  

Total Revenue

  $ 25,902     $ 31,418  
Revenue From Contract With Customer, Milestone Payments [Table Text Block]
   

Research, Development, Regulatory & Commercial Milestones

   

Sales Milestones

 

AstraZeneca

  $ 702     $ 3,925  

Servier

    20        

Seagen

    759       450  

Boston Pharmaceuticals

    88       265  

Genentech

    834       600  

Total potential milestone payments

  $ 2,403     $ 5,240